Skip to Main Content

Paper Details

Longitudinal Assessment of SARS-CoV-2 Antinucleocapsid and Antispike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection.
J Appl Lab Med
5
2021
Anti-SARS-CoV-2 S, Antispike-1-RBD Antibody, COVID-19, RBD, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 Antinucleocapsid, anti-N, anti-S1-, anti-S1-RBD, anti-S1-RBD antibodies
Antibodies, Viral, COVID-19, COVID-19 Testing, Europe, Humans, Longitudinal Studies, Nucleocapsid, Polymerase Chain Reaction, Predictive Value of Tests, Reagent Kits, Diagnostic, SARS-CoV-2, Spike Glycoprotein, Coronavirus, United States
Author NameAffiliation
Joe M El-KhouryYale University
Wade Schulz (CM4AI)Yale University
Thomas J S DurantYale University
  • 1 - 3

Datasets

Release 1.2